# `isb-cgc-bq.HTAN_versioned.clinical_tier1_diagnosis_r2.md`

## Column details

* [STRING]    `Component`
  - Category of metadata (e.g. Diagnosis, Biospecimen, scRNA-seq Level 1, etc.); provide the same one for all items/rows.
* [STRING]    `HTAN_Participant_ID`
  - HTAN ID associated with a patient based on HTAN ID SOP (eg HTANx_yyy )
* [STRING]    `Age_at_Diagnosis`
  - Age at the time of diagnosis expressed in number of days since birth.
* [STRING]    `Year_of_Diagnosis`
  - Numeric value to represent the year of an individual's initial pathologic diagnosis of cancer.
* [STRING]    `Primary_Diagnosis`
  - Text term used to describe the patient's histologic diagnosis, as described by the World Health Organization's (WHO) International Classification of Diseases for Oncology (ICD-O).
* [STRING]    `Site_of_Resection_or_Biopsy`
  - The text term used to describe the anatomic site of origin, of the patient's malignant disease, as described by the World Health Organization's (WHO) International Classification of Diseases for Oncology (ICD-O).
* [STRING]    `Tissue_or_Organ_of_Origin`
  - The text term used to describe the anatomic site of origin, of the patient's malignant disease, as described by the World Health Organization's (WHO) International Classification of Diseases for Oncology (ICD-O).
* [STRING]    `Morphology`
  - The third edition of the International Classification of Diseases for Oncology, published in 2000 used principally in tumor and cancer registries for coding the site (topography) and the histology (morphology) of neoplasms. The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs. In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains. A system of numbered categories for representation of data.
* [STRING]    `Tumor_Grade`
  - Numeric value to express the degree of abnormality of cancer cells, a measure of differentiation and aggressiveness.
* [STRING]    `Progression_or_Recurrence`
  - Yes/No/unknown indicator to identify whether a patient has had a new tumor event after initial treatment.
* [STRING]    `Last_Known_Disease_Status`
  - Text term that describes the last known state or condition of an individual's neoplasm.
* [STRING]    `Days_to_Last_Follow_up`
  - Time interval from the date of last follow up to the date of initial pathologic diagnosis, represented as a calculated number of days.
* [STRING]    `Days_to_Last_Known_Disease_Status`
  - Time interval from the date of last follow up to the date of initial pathologic diagnosis, represented as a calculated number of days.
* [STRING]    `Method_of_Diagnosis`
  - Text term used to describe the method used to confirm the patients malignant diagnosis.
* [STRING]    `Prior_Malignancy`
  - The yes/no/unknown indicator used to describe the patient's history of prior cancer diagnosis.
* [STRING]    `Prior_Treatment`
  - A yes/no/unknown/not applicable indicator related to the administration of therapeutic agents received before the body specimen was collected.
* [STRING]    `Metastasis_at_Diagnosis`
  - The text term used to describe the extent of metastatic disease present at diagnosis.
* [STRING]    `Metastasis_at_Diagnosis_Site`
  - Text term to identify an anatomic site in which metastatic disease involvement is found.
* [STRING]    `First_Symptom_Prior_to_Diagnosis`
  - Text term used to describe the patient's first symptom experienced prior to diagnosis and thought to be related to the disease.
* [STRING]    `Days_to_Diagnosis`
  - Number of days between the date used for index and the date the patient was diagnosed with the malignant disease.
* [STRING]    `Percent_Tumor_Invasion`
  - The percentage of tumor cells spread locally in a malignant neoplasm through infiltration or destruction of adjacent tissue.
* [STRING]    `Residual_Disease`
  - Text terms to describe the status of a tissue margin following surgical resection.
* [STRING]    `Synchronous_Malignancy`
  - A yes/no/unknown indicator used to describe whether the patient had an additional malignant diagnosis at the same time the tumor used for sequencing was diagnosed. If both tumors were sequenced, both tumors would have synchronous malignancies.
* [STRING]    `Tumor_Confined_to_Organ_of_Origin`
  - The yes/no/unknown indicator used to describe whether the tumor is confined to the organ where it originated and did not spread to a proximal or distant location within the body.
* [STRING]    `Tumor_Focality`
  - The text term used to describe whether the patient's disease originated in a single location or multiple locations.
* [STRING]    `Tumor_Largest_Dimension_Diameter`
  - Numeric value used to describe the maximum diameter or dimension of the primary tumor, measured in centimeters.
* [STRING]    `Gross_Tumor_Weight`
  - Numeric value used to describe the gross pathologic tumor weight, measured in grams.
* [STRING]    `Breslow_Thickness`
  - The number that describes the distance, in millimeters, between the upper layer of the epidermis and the deepest point of tumor penetration.
* [STRING]    `Vascular_Invasion_Present`
  - The yes/no indicator to ask if large vessel or venous invasion was detected by surgery or presence in a tumor specimen.
* [STRING]    `Vascular_Invasion_Type`
  - Text term that represents the type of vascular tumor invasion.
* [STRING]    `Anaplasia_Present`
  - Yes/no/unknown/Not Reported indicator used to describe whether anaplasia was present at the
time of diagnosis.
* [STRING]    `Anaplasia_Present_Type`
  - The text term used to describe the morphologic findings indicating the presence of a malignant cellular infiltrate characterized by the presence of large pleomorphic cells, necrosis, and high mitotic activity in a tissue sample.
* [STRING]    `Laterality`
  - For tumors in paired organs, designates the side on which the cancer originates.
* [STRING]    `Perineural_Invasion_Present`
  - A yes/no indicator to ask if perineural invasion or infiltration of tumor or cancer is present.
* [STRING]    `Lymphatic_Invasion_Present`
  - A yes/no indicator to ask if small or thin-walled vessel invasion is present, indicating lymphatic involvement
* [STRING]    `Lymph_Nodes_Positive`
  - The number of lymph nodes involved with disease as determined by pathologic examination.
* [STRING]    `Lymph_Nodes_Tested`
  - The number of lymph nodes tested to determine whether lymph nodes were involved with disease as determined by a pathologic examination.
* [STRING]    `Peritoneal_Fluid_Cytological_Status`
  - The text term used to describe the malignant status of the peritoneal fluid determined by cytologic testing.
* [STRING]    `Classification_of_Tumor`
  - Text that describes the kind of disease present in the tumor specimen as related to a specific timepoint.
* [STRING]    `Best_Overall_Response`
  - The best improvement achieved throughout the entire course of protocol treatment.
* [STRING]    `Mitotic_Count`
  - The number of mitoses identified under the microscope in tumors. The method of counting varies, according to the specific tumor examined. Usually, the mitotic count is determined based on the number of mitoses per high power field (40X) or 10 high power fields.
* [STRING]    `AJCC_Clinical_M`
  - Extent of the distant metastasis for the cancer based on evidence obtained from clinical
 assessment parameters determined prior to treatment.
* [STRING]    `AJCC_Clinical_N`
  - Extent of the regional lymph node involvement for the cancer based on evidence obtained from
 clinical assessment parameters determined prior to treatment.
* [STRING]    `AJCC_Clinical_Stage`
  - Stage group determined from clinical information on the tumor (T), regional node (N) and
 metastases (M) and by grouping cases with similar prognosis for cancer.
* [STRING]    `AJCC_Clinical_T`
  - Extent of the primary cancer based on evidence obtained from clinical assessment parameters
 determined prior to treatment.
* [STRING]    `AJCC_Pathologic_M`
  - Code to represent the defined absence or presence of distant spread or metastases (M) to
 locations via vascular channels or lymphatics beyond the regional lymph nodes, using
 criteria established by the American Joint Committee on Cancer (AJCC).
* [STRING]    `AJCC_Pathologic_N`
  - The codes that represent the stage of cancer based on the nodes present (N stage) according
 to criteria based on multiple editions of the AJCC's Cancer Staging Manual.
* [STRING]    `AJCC_Pathologic_Stage`
  - The extent of a cancer, especially whether the disease has spread from the original site to
 other parts of the body based on AJCC staging criteria.
* [STRING]    `AJCC_Pathologic_T`
  - Code of pathological T (primary tumor) to define the size or contiguous extension of the
 primary tumor (T), using staging criteria from the American Joint Committee on Cancer
 (AJCC).
* [STRING]    `AJCC_Staging_System_Edition`
  - The text term used to describe the version or edition of the American Joint Committee on Cancer
 Staging Handbooks, a publication by the group formed for the purpose of developing a system of
 staging for cancer that is acceptable to the American medical profession and is compatible with
 other accepted classifications.
* [STRING]    `Cog_Neuroblastoma_Risk_Group`
  - Text term that represents the categorization of patients on the basis of prognostic factors per a system developed by Children's Oncology Group (COG). Risk level is used to assign treatment intensity.
* [STRING]    `Cog_Rhabdomyosarcoma_Risk_Group`
  - Text term used to describe the classification of rhabdomyosarcoma, as defined by the Children's Oncology Group (COG).
* [STRING]    `Gleason_Grade_Group`
  - The text term used to describe the overall grouping of grades defined by the Gleason grading classification, which is used to determine the aggressiveness of prostate cancer. Note that this grade describes the entire prostatectomy specimen and is not specific to the sample used for sequencing.
* [STRING]    `Gleason_Grade_Tertiary`
  - The text term used to describe the tertiary pattern as described by the Gleason Grading System.
* [STRING]    `Gleason_Patterns_Percent`
  - Numeric value that represents the percentage of Patterns 4 and 5, which is used when the Gleason score is greater than 7 to predict prognosis.
* [STRING]    `Greatest_Tumor_Dimension`
  - Numeric value that represents the measurement of the widest portion of the tumor in centimeters.
* [STRING]    `IGCCCG_Stage`
  - The text term used to describe the International Germ Cell Cancer Collaborative Group (IGCCCG), a grouping used to further classify metastatic testicular tumors.
* [STRING]    `INPC_Grade`
  - Text term used to describe the classification of neuroblastic differentiation within neuroblastoma tumors, as defined by the International Neuroblastoma Pathology Classification (INPC).
* [STRING]    `INPC_Histologic_Group`
  - The text term used to describe the classification of neuroblastomas distinguishing between favorable and unfavorable histologic groups. The histologic score, defined by the International Neuroblastoma Pathology Classification (INPC), is based on age, mitosis-karyorrhexis index (MKI), stromal content and degree of tumor cell differentiation.
* [STRING]    `INRG_Stage`
  - The text term used to describe the staging classification of neuroblastic tumors, as defined by the International Neuroblastoma Risk Group (INRG).
* [STRING]    `INSS_Stage`
  - Text term used to describe the staging classification of neuroblastic tumors, as defined by the International Neuroblastoma Staging System (INSS).
* [STRING]    `International_Prognostic_Index`
  - The text term used to describe the International Prognostic Index, which classifies the prognosis of patients with aggressive non-Hodgkin's lymphoma.
* [STRING]    `IRS_Group`
  - Text term used to describe the classification of rhabdomyosarcoma tumors, as defined by the Intergroup Rhabdomyosarcoma Study (IRS).
* [STRING]    `IRS_Stage`
  - The text term used to describe the classification of rhabdomyosarcoma tumors, as defined by the Intergroup Rhabdomyosarcoma Study (IRS).
* [STRING]    `ISS_Stage`
  - The multiple myeloma disease stage at diagnosis.
* [STRING]    `Lymph_Node_Involved_Site`
  - The text term used to describe the anatomic site of lymph node involvement.
* [STRING]    `Margin_Distance`
  - Numeric value (in centimeters) that represents the distance between the tumor and the surgical margin.
* [STRING]    `Margins_Involved_Site`
  - The text term used to describe the anatomic sites that were involved in the survival margins.
* [STRING]    `Medulloblastoma_Molecular_Classification`
  - The text term used to describe the classification of medulloblastoma tumors based on molecular features.
* [STRING]    `Micropapillary_Features`
  - The yes/no/unknown indicator used to describe whether micropapillary features were determined to be present.
* [STRING]    `Mitosis_Karyorrhexis_Index`
  - Text term that represents the component of the International Neuroblastoma Pathology Classification (INPC) for mitosis-karyorrhexis index (MKI).
* [STRING]    `Non_Nodal_Regional_Disease`
  - The text term used to describe whether the patient had non-nodal regional disease.
* [STRING]    `Non_Nodal_Tumor_Deposits`
  - The yes/no/unknown indicator used to describe the presence of tumor deposits in the pericolic or perirectal fat or in adjacent mesentery away from the leading edge of the tumor.
* [STRING]    `Ovarian_Specimen_Status`
  - The text term used to describe the physical condition of the involved ovary.
* [STRING]    `Ovarian_Surface_Involvement`
  - The text term that describes whether the surface tissue (outer boundary) of the ovary shows evidence of involvement or presence of cancer.
* [STRING]    `Pregnant_at_Diagnosis`
  - The text term used to indicate whether the patient was pregnant at the time they were diagnosed.
* [STRING]    `Primary_Gleason_Grade`
  - The text term used to describe the primary Gleason score, which describes the pattern of cells making up the largest area of the tumor. The primary and secondary Gleason pattern grades are combined to determine the patient's Gleason grade group, which is used to determine the aggresiveness of prostate cancer. Note that this grade describes the entire prostatectomy specimen and is not specific to the sample used for sequencing.
* [STRING]    `Secondary_Gleason_Grade`
  - The text term used to describe the secondary Gleason score, which describes the pattern of cells making up the second largest area of the tumor. The primary and secondary Gleason pattern grades are combined to determine the patient's Gleason grade group, which is used to determine the aggresiveness of prostate cancer. Note that this grade describes the entire prostatectomy specimen and is not specific to the sample used for sequencing.
* [STRING]    `Supratentorial_Localization`
  - Text term to specify the location of the supratentorial tumor.
* [STRING]    `Tumor_Depth`
  - Numeric value that represents the depth of tumor invasion, measured in millimeters (mm).
* [STRING]    `WHO_CNS_Grade`
  - WHO CNS Grade
* [STRING]    `WHO_NTE_Grade`
  - WHO NTE Grade
* [STRING]    `Days_to_Progression`
  - Number of days between the date used for index and the date the patient's disease progressed.
* [STRING]    `Days_to_Progression_Free`
  - Number of days between the date used for index and the date the patient's disease was formally confirmed as progression-free.
* [STRING]    `NCI_Atlas_Cancer_Site`
  - The primary tumor site used to calculate the incidence rate using the NCI Cancer Atlas, a digital atlas which provides geographical data related to cancer utilizing the Surveillance, Epidemiology, and End Results (SEER) Program cancer incidence rates for 2013 to 2017
* [STRING]    `Progression_or_Recurrence_Type`
  - The text term used to describe the type of progressive or recurrent disease or relapsed disease.
* [STRING]    `Sentinel_Lymph_Node_Count`
  - Numeric count of sentinel lymph nodes.
* [STRING]    `Sentinel_Node_Positive_Assessment_Count`
  - The number or amount of metastatic neoplasms related to the confirmed presence of disease or specific microorganisms during examination of the first rounded mass of lymphatic tissue to which cancer is likely to spread from the primary tumor.
* [STRING]    `Tumor_Extranodal_Extension_Indicator`
  - The indicator to determine extranodal involvement or extent of the disease.
* [STRING]    `Satellite_Metastasis_Present_Indicator`
  - A yes/no indicator to ask if intransit metastases or satellite lesions are present.
* [STRING]    `Other_Biopsy_Resection_Site`
  - A description of the location on or within the human body where the surgical biopsy/resection procedure was performed (Not covered under HTAN Clinical Data Tier 1)
* [STRING]    `Extent_of_Tumor_Resection`
  - The degree to which the lesion has been cut out, or resected.
* [STRING]    `Precancerous_Condition_Type`
  - The classification of pre-cancerous cells found in a specific collection of data being studied by the Consortium for Molecular and Cellular Characterization of Screen-Detected Lesions (MCL).
* [STRING]    `Mode_of_Cancer_Detection`
  - Text term used to describe the mode of cancer detection, like standard of care screening or random detection
* [STRING]    `Topography_Code`
  - Topography Code, indicating site within the body, based on ICD-O-3.
* [STRING]    `Additional_Topography`
  - Topography not included in the ICD-O-3 Topography codes.
* [STRING]    `entityId`
  - Synapse ID of entity
* [STRING]    `HTAN_Center`
  - Name of HTAN Center e.g. HTAN HTAPP
* [STRING]    `Data_Release`
  - Inclusion in HTAN Data Release e.g. Release 1.0

